Published on in Vol 7, No 5 (2021): May
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/27609, first published
.
Journals
- Vulturar D, Neag M, Vesa Ș, Maierean A, Gherman D, Buzoianu A, Orăsan O, Todea D. Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection. International Journal of Molecular Sciences 2022;23(22):14462 View
- Edinoff A, Alpaugh E, Newgaard O, Wajid I, Klapper R, Cornett E, Kaye A, Iyer P, Kaye A. Tocilizumab for Severe COVID-19 Infection and Multisystem Inflammatory Syndrome in Adults and Children. Life 2023;13(4):889 View
- Al-Mistarehi A, El-Akawi S, Kheirallah K, Bani Ata E, Zaitoun K, Khassawneh A, Jarrah A, Alzoubi H, Al-Azzam S, Karasneh R, Altawalbeh R, Khassawneh B. Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study. Cureus 2024 View
- Luo Q, Zheng Y, Zhang J. Combination Therapies against COVID-19. Frontiers in Bioscience-Landmark 2022;27(9) View